G
Gideon Koren
Researcher at Ariel University
Publications - 2007
Citations - 88165
Gideon Koren is an academic researcher from Ariel University. The author has contributed to research in topics: Pregnancy & Population. The author has an hindex of 129, co-authored 1994 publications receiving 81718 citations. Previous affiliations of Gideon Koren include McGill University Health Centre & University of Western Ontario.
Papers
More filters
Journal ArticleDOI
Findings in children exposed in utero to phenytoin and carbamazepine monotherapy : Independent effects of epilepsy and medications
TL;DR: High forehead, frontal bossing, malar hypoplasia, epicanthus and micrognathia were associated with untreated epilepsy, as well as with DPH and CBZ treatment, and increased rates of hypertelorism were detected among DPH-exposed offspring.
Journal ArticleDOI
Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk
TL;DR: Although short‐term adverse effects in the infant from exposure through nursing were not reported in this cohort, future studies that assess the potential long‐term consequences are needed.
Journal ArticleDOI
Characteristics of Opioid-Users Whose Death Was Related to Opioid-Toxicity: A Population-Based Study in Ontario, Canada
TL;DR: These results identify novel, susceptible groups of opioid-users whose cause of death was related to opioids in Ontario and provide the first evidence to assist in quantifying the contribution of opioid misuse and diversion amongst opioid-related mortality in Canada.
Journal ArticleDOI
Drugs of abuse testing in meconium.
TL;DR: A method has been developed for the analysis of fatty acid ethyl esters in meconium as a biomarker of fetal alcohol exposure, potentially facilitating the future diagnosis of Fetal Alcohol Spectrum Disorder in situations where gestational alcohol consumption history is unknown.
Journal ArticleDOI
Risks and benefits of β-receptor blockers for pregnancy hypertension: overview of the randomized trials
TL;DR: It is not clear that the benefits outweigh the risks when beta-blockers are used to treat mild to moderate chronic or pregnancy-induced hypertension, given the unknown overall effect on perinatal outcomes.